STOCK TITAN

GSK executives acquire ADS via dividend reinvestment

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

GSK plc reported four ADS acquisitions by three executives on November 13, 2026. Non-Executive Director Dr Hal Barron, SVP and Group General Counsel James Ford, and President, US Maya Martinez-Davis acquired 2,259.160, 53.408, and 81.902 notional ADS, respectively, in their GSK Executive Supplemental Savings Plan accounts following dividend reinvestment. Each was priced at $50.4500 per ADS. Dr Barron also acquired 72 ADS in his 401(k) plan account following dividend reinvestment at the same price. The transactions were reported at the New York Stock Exchange.

Price per ADS $50.4500 Reported for all four acquisitions on November 13, 2026
Notional ADS acquired by Dr Hal Barron 2,259.160 ADS GSK Executive Supplemental Savings Plan account
Notional ADS acquired by James Ford 53.408 ADS GSK Executive Supplemental Savings Plan account
Notional ADS acquired by Maya Martinez-Davis 81.902 ADS GSK Executive Supplemental Savings Plan account
ADS acquired by Dr Hal Barron 72 ADS GSK 401(k) plan account
American Depositary Shares financial
"Description of the financial instrument: American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
notional ADS financial
"Acquisition of notional ADS within Dr Barron’s GSK Executive Supplemental Savings Plan account"
GSK Executive Supplemental Savings Plan financial
"within Mr Ford’s GSK Executive Supplemental Savings Plan account"
reinvestment of dividends financial
"following the reinvestment of dividends"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which GSK executives acquired ADS on November 13, 2026, and how many?

GSK reported that Dr Hal Barron, James Ford, and Maya Martinez-Davis acquired 2,259.160, 53.408, and 81.902 notional ADS, respectively, in executive supplemental savings plan accounts. Dr Barron also acquired 72 ADS in a 401(k) plan account.

What price were the GSK ADS acquisitions reported at?

The four reported acquisitions were priced at $50.4500 per ADS on November 13, 2026. The transactions followed dividend reinvestment and were reported at the New York Stock Exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
  
 
For the month of November 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
GSK plc (the ‘Company’)
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Dr Hal Barron
 
b)
Position/status
Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Acquisition of notional ADS within Dr Barron’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$50.4500
2,259.160
 
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume Price
 
 
e)
Date of the transaction
2026-11-13
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
James Ford
 
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Acquisition of notional ADS within Mr Ford’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$50.4500
 
53.408
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
 
Aggregated volume Price
 
 
e)
Date of the transaction
2026-11-13
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
  
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Maya Martinez-Davis
 
b)
Position/status
President, US
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Acquisition of notional ADS within Ms Martinez-Davis’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$50.4500
 
81.902
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume Price
 
 
e)
Date of the transaction
2026-11-13
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
1.
Details of PDMR/person closely associated with them (‘PCA’)
 
a)
Name
Dr Hal Barron
 
b)
Position/status
Non-Executive Director
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares (‘ADS’)
 
ISIN: US37733W2044
 
b)
Nature of the transaction
Acquisition of ADS within Dr Barron’s GSK 401(k) plan account following the reinvestment of dividends
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
$50.4500
 
72
 
 
 
 
 
d)
Aggregated information
 
N/A (single transaction)
Aggregated volume Price
 
 
e)
Date of the transaction
2026-11-13
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
  
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
  
Registered in England & Wales:
No. 3888792

Registered Office: 
79 New Oxford Street
London
WC1A 1DG
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: November 17, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc

Keep reading